Journal article · 2026 · Open access

CCR7+ activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity

Maria A. Koufaki, Erin Richardson, Eduardo Bonavita, Richard Reeves, Agrin Moeini, Shih‐Chieh Chiang, Antonia Banyard, Massimo Russo, Charles H. Earnshaw, Charlotte R. Bell, Eimear Flanagan, Victoria S. Pelly and 9 more

Immunity, 59(8), 2282–2298.e10 · Published 1 August 2026 · DOI 10.1016/j.immuni.2026.07.002

Open full textCite this paper

In brief

“CCR7+ activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity” is a 2026 journal article by Maria A. Koufaki and 20 co-authors, published in Immunity. OpenAlex counts 7 citations as of 18 November 2026. It is open access under a CC BY licence: the full text is free to read at Immunity.

Citations
7
Most cited in
2026 (6)
Field-weighted impact
11.41
References
89
Authors
21

Abstract

Single-cell transcriptomics identifies a convergent activation state of conventional dendritic cells (cDCs) shared by type 1 and type 2 cDCs (cDC1s and cDC2s). These activated DCs (actDCs) are characterized by co-expression of T cell-stimulating and inhibitory molecules. Here, we examined the functional contribution of actDCs to anti-tumor immunity by developing mouse models that leverage CCR7 expression to conditionally label or ablate actDCs. The capacity of cDCs to stimulate tumor-specific cytotoxic T lymphocytes (CTLs) was restricted to the actDC state. cDC1- and cDC2-derived actDCs supported CTL priming through cross-presentation and cross-dressing, respectively, with the latter occurring in a cancer type-dependent manner. actDCs were required for the activation of naive CTLs in tumor-draining lymph nodes and for sustaining effector CTL function within tumors. Consequently, ablation of actDCs impaired spontaneous tumor control and responses to immune checkpoint blockade or adoptive T cell therapy. Thus, the actDC state emerges as a critical determinant of cDC-mediated anti-tumor immunity.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Koufaki, M. A., Richardson, E., Bonavita, E., Reeves, R., Moeini, A., Chiang, S., Banyard, A., Russo, M., Earnshaw, C. H., Bell, C. R., Flanagan, E., Pelly, V. S., Nebot-Bral, L., Pidoux, A., Dunn, P., Sahoo, S., Henri, S., MALISSEN, B., MacDonald, A. S., . . . Zelenay, S. (2026). CCR7+ activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity. Immunity, 59(8), 2282–2298.e10. https://doi.org/10.1016/j.immuni.2026.07.002

MLA 9

Koufaki, Maria A., et al. “CCR7+ activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity.” Immunity, vol. 59, no. 8, 2026, pp. 2282–2298.e10. https://doi.org/10.1016/j.immuni.2026.07.002.

Chicago

Koufaki, Maria A., Erin Richardson, Eduardo Bonavita, Richard Reeves, Agrin Moeini, Shih‐Chieh Chiang, Antonia Banyard, et al. 2026. “CCR7+ activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity.” Immunity 59 (8): 2282–2298.e10. https://doi.org/10.1016/j.immuni.2026.07.002.

Harvard

Koufaki, M. A. et al. (2026) ‘CCR7+ activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity’, Immunity, 59(8), pp. 2282–2298.e10. doi:10.1016/j.immuni.2026.07.002.

IEEE

M. A. Koufaki et al., “CCR7+ activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity,” Immunity, vol. 59, no. 8, pp. 2282–2298.e10, 2026, doi: 10.1016/j.immuni.2026.07.002.

BibTeX

@article{koufaki2026activated,
  title     = {{CCR7+ activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity}},
  author    = {Koufaki, Maria A. and Richardson, Erin and Bonavita, Eduardo and Reeves, Richard and Moeini, Agrin and Chiang, Shih‐Chieh and Banyard, Antonia and Russo, Massimo and Earnshaw, Charles H. and Bell, Charlotte R. and Flanagan, Eimear and Pelly, Victoria S. and Nebot-Bral, Laëtitia and Pidoux, Anna and Dunn, Poppy and Sahoo, Sudhakar and Henri, Sandrine and MALISSEN, Bernard and MacDonald, Andrew S. and Moncaut, Natalia and Zelenay, Santiago},
  journal   = {Immunity},
  year      = {2026},
  volume    = {59},
  number    = {8},
  pages     = {2282--2298.e10},
  doi       = {10.1016/j.immuni.2026.07.002},
  url       = {https://doi.org/10.1016/j.immuni.2026.07.002}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses

  • myeloid dendritic cells
  • CCR7
  • dendritic cell activation
  • antitumor immunity
  • cDC1
  • cdc2
  • cross-presentation
  • cross-dressing

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Koufaki, M. A., Richardson, E., Bonavita, E., Reeves, R., Moeini, A., Chiang, S., Banyard, A., Russo, M., Earnshaw, C. H., Bell, C. R., Flanagan, E., Pelly, V. S., Nebot-Bral, L., Pidoux, A., Dunn, P., Sahoo, S., Henri, S., MALISSEN, B., MacDonald, A. S., . . . Zelenay, S. (2026). CCR7+ activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity. Immunity, 59(8), 2282–2298.e10. https://doi.org/10.1016/j.immuni.2026.07.002

How many times has this paper been cited?

7 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Immunity: sign in and open the full text from this page.

Who wrote this paper?

Maria A. Koufaki, Erin Richardson, Eduardo Bonavita, Richard Reeves, Agrin Moeini, Shih‐Chieh Chiang, Antonia Banyard, Massimo Russo, Charles H. Earnshaw, Charlotte R. Bell, Eimear Flanagan, Victoria S. Pelly and 9 more.

What is the DOI of this paper?

10.1016/j.immuni.2026.07.002, permanently at https://doi.org/10.1016/j.immuni.2026.07.002. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.